Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Withdraws Complete Genomics Bid

NEW YORK (GenomeWeb News) — Illumina has withdrawn its offer to acquire Complete Genomics, according to a filing submitted to the US Securities and Exchange today.

According to the filing, Illumina has also notified the Federal Trade Commission that it is withdrawing a Hart-Scott-Rodino merger prenotification filing related to the proposed acquisition.

Illumina made an unsolicited bid for Complete Genomics last November, offering $3.30 per share for the company — a bid 5 percent above that of BGI-Shenzhen, which in September offered approximately $118 million for the sequencing services firm.

Yesterday, BGI and Complete Genomics announced that the FTC had granted early termination of the Hart-Scott-Rodino waiting period for their proposed merger.

Illumina's proposal, meantime, was the subject of several information requests from the FTC. Complete Genomics had cited the fact that the agreement would not receive antitrust clearance as a key factor in rejecting Illumina's bid.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.